<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764777</url>
  </required_header>
  <id_info>
    <org_study_id>FMRP-006</org_study_id>
    <nct_id>NCT00764777</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions</brief_title>
  <acronym>BRAVISSIMO</acronym>
  <official_title>Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C &amp; D Iliac Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BRAVISSIMO trial wants to investigate in a controlled setting, the long-term (up to 24&#xD;
      months) outcome of the self-expanding nitinol Absolute Pro (Abbott Vascular) and the&#xD;
      balloon-expandable Omnilink Elite (Abbott Vascular) stent in TASC A&amp;B and TASC C&amp;D iliac&#xD;
      lesions. A separate analysis of both patient populations will be performed and listed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.0) and without TLR</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success, defined as the ability to achieve final residual angiographic stenosis no greater than 30%</measure>
    <time_frame>Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency rate at different follow-up times defined as absence of hemodynamically significant stenosis at the target area on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.0) and without prior TLR.</measure>
    <time_frame>1, 6 &amp; 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) Clinical success at follow-up is defined as an improvement of Rutherford classification at different follow-ups of one class or more as compared to the pre-procedure Rutherford classification.</measure>
    <time_frame>1, 6, 12 &amp; 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>1, 6, 12, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">325</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Intermittent Claudication</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iliac stenting</intervention_name>
    <description>Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents</description>
    <arm_group_label>Stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        GENERAL&#xD;
&#xD;
          -  Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable&#xD;
             for stenting (on indication for primary stenting, based on the discretion of the&#xD;
             investigator)&#xD;
&#xD;
          -  Patient presenting a score from 2 to 5 following Rutherford classification&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times for the duration of the study&#xD;
&#xD;
          -  Patient is &gt;18 years old&#xD;
&#xD;
          -  Patient (or their legal representative) understands the nature of the procedure and&#xD;
             provides written informed consent, prior to enrolment in the study&#xD;
&#xD;
          -  Patient is eligible for treatment with the Absolute Pro or Omnilink Elite (Abbott&#xD;
             Vascular)&#xD;
&#xD;
        ANGIOGRAPHIC&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class A, B, C or D lesion with one of&#xD;
             the listed specifications:&#xD;
&#xD;
          -  Type A lesions&#xD;
&#xD;
          -  Unilateral or bilateral stenoses of the Common Iliac Artery&#xD;
&#xD;
          -  Unilateral or bilateral single short (≤3 cm) stenosis of the External Iliac Artery&#xD;
&#xD;
          -  Type B lesions&#xD;
&#xD;
          -  Unilateral Common Iliac Artery occlusion&#xD;
&#xD;
          -  Single or multiple stenosis totaling 3-10 cm involving the External Iliac Artery not&#xD;
             extending into the Common Femoral Artery&#xD;
&#xD;
          -  Unilateral External Iliac Artery occlusion not involving the origins of Internal Iliac&#xD;
             Artery or Common Iliac Artery&#xD;
&#xD;
          -  Type C lesions&#xD;
&#xD;
          -  Bilateral Common Iliac Artery occlusions&#xD;
&#xD;
          -  Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the Common&#xD;
             Femoral Artery&#xD;
&#xD;
          -  Unilateral External Iliac Artery stenosis extending into the Common Femoral Artery&#xD;
&#xD;
          -  Unilateral External Iliac Artery occlusion that involves the origins of the Internal&#xD;
             Iliac and/or Common Femoral Artery&#xD;
&#xD;
          -  Heavily calcified unilateral External Iliac Artery occlusion with or without&#xD;
             involvement of origins of the Internal Iliac and/or Common Femoral Artery&#xD;
&#xD;
          -  Type D lesions&#xD;
&#xD;
          -  Unilateral occlusions of both Common Iliac and External Iliac Artery&#xD;
&#xD;
          -  Diffuse disease involving the aorta and both iliac arteries requiring treatment&#xD;
&#xD;
          -  Diffuse multiple stenoses involving the unilateral Common Iliac, External Iliac and&#xD;
             Common Femoral Artery&#xD;
&#xD;
          -  Bilateral occlusions of External Iliac Artery&#xD;
&#xD;
          -  The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or&#xD;
             occlusion which can be passed with standard guidewire manipulation&#xD;
&#xD;
          -  There is angiographic evidence of a patent Common an Deep Femoral Artery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The target lesion is either a modified TASC-II class B or D lesion with aortic lesion&#xD;
             involvement:&#xD;
&#xD;
          -  Type B lesions&#xD;
&#xD;
          -  Short (≤3 cm) stenosis of infrarenal aorta&#xD;
&#xD;
          -  Type D lesions&#xD;
&#xD;
          -  Infra-renal aortoiliac occlusion&#xD;
&#xD;
          -  Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring treatment&#xD;
             and not amenable to endograft placement or other lesions requiring open aortic or&#xD;
             iliac surgery&#xD;
&#xD;
          -  Presence of aneurysm at the level of the iliac arteries&#xD;
&#xD;
          -  Previously implanted stent(s) at the same lesion site&#xD;
&#xD;
          -  Reference segment diameter is not suitable for available stent design&#xD;
&#xD;
          -  Untreatable lesion located at the distal outflow arteries&#xD;
&#xD;
          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation&#xD;
             therapy) as part of the index procedure&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
&#xD;
          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion&#xD;
             site&#xD;
&#xD;
          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium&#xD;
&#xD;
          -  Patients with a history of prior life-threatening contrast medium reaction&#xD;
&#xD;
          -  Patients with known hypersensitivity to nickel-titanium&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Life expectancy of less than twelve months&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow up period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bosiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint-Blasius, Dendermonde, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Campus Sint-Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.fmrp.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Intermittent Claudication</keyword>
  <keyword>Critical limb Ischemia</keyword>
  <keyword>TASC A</keyword>
  <keyword>TASC B</keyword>
  <keyword>TASC C</keyword>
  <keyword>TASC D</keyword>
  <keyword>balloon-expandable stent</keyword>
  <keyword>Self-expanding stent</keyword>
  <keyword>TASC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

